Trials / Completed
CompletedNCT04718103
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 397 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK3511294 | GSK3511294 was administered using a pre-filled syringe. |
| BIOLOGICAL | Placebo | Placebo was administered as normal saline using a pre-filled syringe. |
Timeline
- Start date
- 2021-02-04
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
- First posted
- 2021-01-22
- Last updated
- 2024-11-29
- Results posted
- 2024-11-29
Locations
129 sites across 11 countries: United States, Australia, Canada, Czechia, France, Hungary, Italy, Japan, Poland, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04718103. Inclusion in this directory is not an endorsement.